Moderna, Inc. Increase (Decrease) in Accounts Payable
Moderna, Inc. (MRNA) reported Increase (Decrease) in Accounts Payable of -$128.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-07-31
- Moderna, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$8.00M.
- Moderna, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$120.00M.
- Moderna, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $22.00M, a 35.29% decline year-over-year.
- Moderna, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $89.00M, a 7.29% decline year-over-year.
- Moderna, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$92.00M.
- Moderna, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$69.00M, a 630.77% decline from fiscal 2023.
- Moderna, Inc. increase (decrease) in accounts payable for fiscal 2023 was $13.00M, a 94.58% decline from fiscal 2022.
- Moderna, Inc. increase (decrease) in accounts payable for fiscal 2022 was $240.00M, a 17.65% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$128.00M 10-Q · filed 2026-07-31 | -$106.00M derived: sum of 3 quarters · filed 2026-07-31 | -$17.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | -$120.00M 10-Q · filed 2026-05-01 | -$98.00M derived: sum of 2 quarters · filed 2026-05-01 | -$9.00M derived: sum of 3 quarters · filed 2026-05-01 | -$56.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $111.00M derived: sum of 2 quarters · filed 2026-02-20 | $64.00M derived: sum of 3 quarters · filed 2026-07-31 | -$92.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $89.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $42.00M derived: sum of 2 quarters · filed 2026-07-31 | -$114.00M 10-Q · filed 2025-11-06 | -$80.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | -$47.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$203.00M 10-Q · filed 2026-07-31 | -$169.00M derived: sum of 3 quarters · filed 2026-07-31 | -$73.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | -$156.00M 10-Q · filed 2026-05-01 | -$122.00M derived: sum of 2 quarters · filed 2026-05-01 | -$26.00M derived: sum of 3 quarters · filed 2026-05-01 | $78.00M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | $34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $130.00M derived: sum of 2 quarters · filed 2026-02-20 | $234.00M derived: sum of 3 quarters · filed 2026-02-20 | -$69.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $96.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $200.00M derived: sum of 2 quarters · filed 2025-11-06 | -$103.00M 10-Q · filed 2025-11-06 | -$82.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $104.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$199.00M 10-Q · filed 2025-08-01 | -$178.00M derived: sum of 3 quarters · filed 2026-02-20 | $1.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | -$303.00M 10-Q · filed 2025-05-01 | -$282.00M derived: sum of 2 quarters · filed 2026-02-20 | -$103.00M derived: sum of 3 quarters · filed 2026-02-20 | -$173.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $200.00M derived: sum of 2 quarters · filed 2026-02-20 | $130.00M derived: sum of 3 quarters · filed 2026-02-20 | $13.00M 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $179.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $109.00M derived: sum of 2 quarters · filed 2024-11-07 | -$8.00M 10-Q · filed 2024-11-07 | $143.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | -$70.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$187.00M 10-Q · filed 2024-08-01 | -$36.00M derived: sum of 3 quarters · filed 2025-02-21 | $109.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | -$117.00M 10-Q · filed 2024-05-02 | $34.00M derived: sum of 2 quarters · filed 2025-02-21 | $179.00M derived: sum of 3 quarters · filed 2025-02-21 | $158.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $151.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $296.00M derived: sum of 2 quarters · filed 2025-02-21 | $275.00M derived: sum of 3 quarters · filed 2025-02-21 | $240.00M 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $145.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $124.00M derived: sum of 2 quarters · filed 2023-11-03 | $89.00M 10-Q · filed 2023-11-03 | $267.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | -$21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$56.00M 10-Q · filed 2023-08-03 | $122.00M derived: sum of 3 quarters · filed 2024-02-23 | $104.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | -$35.00M 10-Q · filed 2023-05-04 | $143.00M derived: sum of 2 quarters · filed 2024-02-23 | $125.00M derived: sum of 3 quarters · filed 2024-02-23 | $184.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $178.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $160.00M derived: sum of 2 quarters · filed 2024-02-23 | $219.00M derived: sum of 3 quarters · filed 2024-02-23 | $204.00M 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | -$18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $41.00M derived: sum of 2 quarters · filed 2022-11-03 | $26.00M 10-Q · filed 2022-11-03 | $24.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $59.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $44.00M 10-Q · filed 2022-08-03 | $42.00M derived: sum of 3 quarters · filed 2023-02-24 | $44.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | -$15.00M 10-Q · filed 2022-05-04 | -$17.00M derived: sum of 2 quarters · filed 2023-02-24 | -$15.00M derived: sum of 3 quarters · filed 2023-02-24 | -$5.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $0.00 derived: sum of 2 quarters · filed 2023-02-24 | $10.00M derived: sum of 3 quarters · filed 2023-02-24 | $12.00M 10-K · filed 2023-02-24 | $11.88M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $12.00M derived: sum of 2 quarters · filed 2021-11-04 | $14.00M 10-Q · filed 2021-11-04 | $13.63M 10-Q · filed 2020-10-30 | $9.19M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $12.00M 10-Q · filed 2021-08-05 | $11.47M 10-Q · filed 2020-08-06 | $7.18M derived: sum of 3 quarters · filed 2022-02-25 | -$10.53M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | $2.00M 10-Q · filed 2021-05-06 | $2.33M 10-Q · filed 2020-05-07 | -$2.81M derived: sum of 2 quarters · filed 2022-02-25 | -$20.53M derived: sum of 3 quarters · filed 2022-02-25 | -$23.73M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$22.53M derived: sum of 2 quarters · filed 2022-02-25 | -$25.73M derived: sum of 3 quarters · filed 2022-02-25 | -$24.00M 10-K · filed 2022-02-25 | -$23.96M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | -$17.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | -$20.92M derived: sum of 2 quarters · filed 2020-10-30 | -$19.18M 10-Q · filed 2020-10-30 | -$4.89M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | -$3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.47M 10-Q · filed 2020-08-06 | $12.83M derived: sum of 3 quarters · filed 2021-02-26 | $14.89M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | $1.73M 10-Q · filed 2020-05-07 | $16.03M derived: sum of 2 quarters · filed 2021-02-26 | $18.09M derived: sum of 3 quarters · filed 2021-02-26 | $15.28M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $16.36M derived: sum of 2 quarters · filed 2021-02-26 | $13.55M derived: sum of 3 quarters · filed 2021-02-26 | $15.02M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$749.00K derived: sum of 2 quarters · filed 2019-11-06 | $718.00K 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | -$2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$1.34M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $1.47M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$12.77M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $5.99M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |